Core Insights - ST Kelly (300326) reported a revenue of 546 million yuan for the first half of 2025, representing a year-on-year increase of 14.75% [1] - The net profit attributable to shareholders reached 43.81 million yuan, showing a significant year-on-year growth of 44.88% [1] Revenue Growth - The increase in revenue is primarily driven by the growth in the vertebroplasty business segment and an increase in trade business income [1] - Revenue from minimally invasive vertebroplasty products amounted to 165 million yuan, reflecting a year-on-year growth of 11.54% [1] Business Strategy - The company focuses on innovation in orthopedic products, exploring new materials, fields, and technologies based on market trends and clinical feedback [1] - ST Kelly is committed to enhancing production efficiency, process innovation, and expanding production scale to reduce production costs [1] - The company continues to strengthen cost control and expense management by compressing labor costs and lowering operating expenses [1] Product and Service Overview - ST Kelly's main business involves the production, research and development, sales, and service of orthopedic implant medical devices, including spinal minimally invasive products and orthopedic trauma implant devices [1] - The wholly-owned subsidiary Elliquence specializes in the research, production, and sales of surgical energy platforms and high-value consumables [1] - The holding subsidiary Jeno Medical provides professional cleaning and sterilization solutions for medical devices, equipment, and healthcare materials [1]